Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
Authors' conclusion
Icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of icosapent ethyl on patient-centered measures of total disease burden.
Study context
- Population
- Statin-treated patients with established CVD or age ≥50 years with DM and ≥1 additional risk factor, fasting TG 1.69–5.63 mmol/L, LDL-C 1.06–2.59 mmol/L
- Participants
- 8,179 patients
- Comparison
- Icosapent ethyl vs placebo
- Primary endpoint
- Total hospitalizations and days lost to hospitalization and death
- Follow-up
- Median 5.0 years
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
median 5.0 years
Icosapent ethyl vs PlaceboEstimate (95% CI)P value
Total hospitalizations
HR 0.91(0.84–0.98)
P = 0.017Survival to study end without hospitalization
OR 1.12(1.02–1.22)
P = 0.016Days lost among those hospitalized or who died
RR 0.93(0.93–0.94)
P < 0.001Original publication
Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT. Eur J Prev Cardiol. Published 16 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →